441 related articles for article (PubMed ID: 34070995)
1. Autophagy Induction as a Host-Directed Therapeutic Strategy against
Adikesavalu H; Gopalaswamy R; Kumar A; Ranganathan UD; Shanmugam S
Medicina (Kaunas); 2021 May; 57(6):. PubMed ID: 34070995
[TBL] [Abstract][Full Text] [Related]
2. Host-Directed Therapeutic Strategies for Tuberculosis.
Kolloli A; Subbian S
Front Med (Lausanne); 2017; 4():171. PubMed ID: 29094039
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Autophagy: A new strategy for host-directed therapy of tuberculosis.
Paik S; Kim JK; Chung C; Jo EK
Virulence; 2019 Dec; 10(1):448-459. PubMed ID: 30322337
[TBL] [Abstract][Full Text] [Related]
5. FDA-Approved Amoxapine Effectively Promotes Macrophage Control of Mycobacteria by Inducing Autophagy.
Wang J; Sha J; Strong E; Chopra AK; Lee S
Microbiol Spectr; 2022 Oct; 10(5):e0250922. PubMed ID: 36129262
[TBL] [Abstract][Full Text] [Related]
6. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
7. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis.
Boland R; Heemskerk MT; Forn-Cuní G; Korbee CJ; Walburg KV; Esselink JJ; Carvalho Dos Santos C; de Waal AM; van der Hoeven DCM; van der Sar E; de Ries AS; Xie J; Spaink HP; van der Vaart M; Haks MC; Meijer AH; Ottenhoff THM
mBio; 2023 Feb; 14(1):e0302422. PubMed ID: 36475748
[TBL] [Abstract][Full Text] [Related]
8. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
9. Harnessing the mTOR Pathway for Tuberculosis Treatment.
Singh P; Subbian S
Front Microbiol; 2018; 9():70. PubMed ID: 29441052
[TBL] [Abstract][Full Text] [Related]
10. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.
Palucci I; Delogu G
Chemotherapy; 2018; 63(3):172-180. PubMed ID: 30032143
[TBL] [Abstract][Full Text] [Related]
11. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
Kiran D; Podell BK; Chambers M; Basaraba RJ
Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
[TBL] [Abstract][Full Text] [Related]
12. Bazedoxifene Suppresses Intracellular Mycobacterium tuberculosis Growth by Enhancing Autophagy.
Ouyang Q; Zhang K; Lin D; Feng CG; Cai Y; Chen X
mSphere; 2020 Apr; 5(2):. PubMed ID: 32269154
[TBL] [Abstract][Full Text] [Related]
13. Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.
Zumla A; Rao M; Dodoo E; Maeurer M
BMC Med; 2016 Jun; 14():89. PubMed ID: 27301245
[TBL] [Abstract][Full Text] [Related]
14. Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.
Abreu R; Giri P; Quinn F
Front Immunol; 2020; 11():1553. PubMed ID: 32849525
[TBL] [Abstract][Full Text] [Related]
15. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
[TBL] [Abstract][Full Text] [Related]
16. Remembering the Host in Tuberculosis Drug Development.
Frank DJ; Horne DJ; Dutta NK; Shaku MT; Madensein R; Hawn TR; Steyn AJC; Karakousis PC; Kana BD; Meintjes G; Laughon B; Tanvir Z
J Infect Dis; 2019 Apr; 219(10):1518-1524. PubMed ID: 30590592
[TBL] [Abstract][Full Text] [Related]
17. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
18. Allicin enhances antimicrobial activity of macrophages during Mycobacterium tuberculosis infection.
Dwivedi VP; Bhattacharya D; Singh M; Bhaskar A; Kumar S; Fatima S; Sobia P; Kaer LV; Das G
J Ethnopharmacol; 2019 Oct; 243():111634. PubMed ID: 30537531
[TBL] [Abstract][Full Text] [Related]
19. Natural products in anti-tuberculosis host-directed therapy.
Huang X; Lowrie DB; Fan XY; Hu Z
Biomed Pharmacother; 2024 Feb; 171():116087. PubMed ID: 38171242
[TBL] [Abstract][Full Text] [Related]
20. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
